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Both phospholipase D1 (PLD1) and PLD2 regulate degranulation when RBL-2H3 cells are stimulated via
the immunoglobulin E receptor, FcRI. However, the activation mechanism for PLD2 is unclear. As reported
here, PLD2 but not PLD1 is phosphorylated through the Src kinases, Fyn and Fgr, and this phosphorylation
appears to regulate PLD2 activation and degranulation. For example, only hemagglutinin-tagged PLD2 was
tyrosine phosphorylated in antigen-stimulated cells that had been made to express HA-PLD1 and HA-PLD2.
This phosphorylation was blocked by a Src kinase inhibitor or by small interfering RNAs directed against Fyn
and Fgr and was enhanced by overexpression of Fyn and Fgr but not by other Src kinases. The phosphorylation
and activity of PLD2 were further enhanced by the tyrosine phosphatase inhibitor, Na3VO4. Mutation of PLD2
at tyrosines 11, 14, 165, or 470 partially impaired, and mutation of all tyrosines blocked, PLD2 phosphorylation
and activation, although two of these mutations were detrimental to PLD2 function. PLD2 phosphorylation
preceded degranulation, both events were equally sensitive to inhibition of Src kinase activity, and both were
enhanced by coexpression of PLD2 and the Src kinases. The findings provide the first description of a
mechanism for activation of PLD2 in a physiological setting and of a role for Fgr in FcRI-mediated signaling.
Phospholipase D (PLD) is activated via receptors in a wide
variety of cells where it is thought to regulate intracellular
signaling processes and functions such as membrane traffick-
ing, cytoskeletal organization, and degranulation of mast cells
(reviewed in references 15, 25, and 31). PLD catalyzes the
hydrolysis of phosphatidylcholine to form phosphatidic acid,
which is rapidly converted to other biologically active mole-
cules, namely, lysophosphatidic acid and diacylglycerol. In the
presence of relatively low concentrations of primary alcohols,
the production of phosphatidic acid is diverted to more meta-
bolically inert phosphatidylalcohols by transphosphatidylation,
a reaction that is unique to PLD and one that is utilized in the
assay of PLD in vivo (39) and to unmask the physiologic roles
of phosphatidic acid (62).
Two isoforms of PLD have been cloned, PLD1 and PLD2,
with PLD1 existing as two variants, PLD1a and PLD1b (11,
21). PLD1 is activated in vitro by small GTPases such as ARF
and Rho and protein kinase C (PKC)  in the presence of
phosphatidylinositol 1,4-bisphosphate (PIP2) (4, 21, 37, 43,
55). There is also evidence that PLD1 can be regulated in vivo
by Rho kinase (48), Ca2/calmodulin-dependent kinase II
(35), and PKC in a catalytically dependent or independent
manner (21, 26, 63). PLD2, in contrast, is activated in vitro by
PIP2 alone, and this activity is minimally affected by the small
GTPases or PKC (11, 32, 54). However, the mechanisms
regulating PLD2 activity in vivo are unclear. There are reports
of tyrosine phosphorylation of PLD1 (33, 36) and PLD2 (1, 44,
51) and indications from pharmacological studies that tyrosine
phosphorylation may regulate PLD activity (6, 27, 36, 44). In
addition, PLD2 was shown to associate with, and be phosphor-
ylated by, the tyrosine kinase receptor for epidermal growth
factor (EGF) (51) and by Src kinase (1, 42). Nevertheless, the
role of such phosphorylation is uncertain. Although tyrosine-
11 was identified as the specific residue phosphorylated in PLD2,
mutation of this site enhanced basal PLD2 activity but had no
effect on the magnitude of the PLD2 response to EGF (51).
Mast cells and blood basophils are responsible for a variety
of allergic disorders (5, 59). These cells respond to immuno-
globulin E (IgE)-directed antigens via the high-affinity recep-
tor for IgE, namely, FcεRI, by release of granules that contain
preformed inflammatory mediators and the generation of in-
flammatory lipids and cytokines. PLD is thought to play an
essential role in mast cell degranulation (7, 10, 58). PLD is
activated in isolated mast cells (12) and cultured mast cell lines
(10, 28, 30) by a variety of stimulants, including antigen. Cross-
linking of the IgE/FcεRI complex with antigen results in the
recruitment and activation of Src kinases and subsequently
other tyrosine kinases. The function of the individual PLD
isoforms in mast cells has been studied in the RBL-2H3 cell
line, which is now known to be an analog of rat mucosal mast
cells (49). Studies with transiently expressed forms of both
PLDs in RBL-2H3 cells indicate that PLD1b and PLD2 asso-
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ciate with granule membranes and the plasma membrane, re-
spectively (7, 9), and that both isoforms are activated upon
antigen stimulation (8, 40). The mechanisms of activation of
these PLDs by antigen are unknown. However, the location of
PLD2 at the plasma membrane makes this isoform particularly
accessible to FcεRI-associated tyrosine kinases.
As reported here, activation of PLD and degranulation in
antigen-stimulated RBL-2H3 cells is inhibited by low concen-
trations of the Src kinase inhibitor PP2. We investigated
whether Src kinases regulate PLD directly by tyrosine phos-
phorylation and, if so, whether this phosphorylation is essential
for degranulation. We show by coexpression studies, site-di-
rected mutagenesis, and the use of small interfering RNAs
(siRNAs) directed against Src kinases that Fyn and Fgr phos-
phorylate PLD2 but not PLD1b in vitro and in vivo and that
this phosphorylation is required for the activation of PLD2 in
vivo. Furthermore, suppression of this phosphorylation or the
activation of PLD2 itself by various strategies also results in
suppression of degranulation in stimulated RBL-2H3 cells.
MATERIALS AND METHODS
Materials. Materials were purchased from the following sources. Piceatannol,
wortmannin, and Ro31-7549 were obtained from Alexis (San Diego, Calif.), and
PP2 was from Calbiochem (La Jolla, Calif.). Antibodies to phosphotyrosine (PY)
(4G10) and Src were from Upstate Biotechnology (Lake Placid, N.Y.). Antibod-
ies to Lyn, Fyn, Fgr, and hemagglutinin (HA) tag were from Santa Cruz Bio-
technology, Inc. (Santa Cruz, Calif.). [3H]myristic acid was from DuPont-NEN
(Boston, Mass.), and [-32P]ATP was from ICN Biomedicals, Inc. (Irvine, Calif.).
Cell culture reagents were from Gibco/Invitrogen (Carlsbad, Calif.). Tris-glycine
polyacrylamide gels were from Novex (San Diego, Calif.), trinitrophenyl (DNP)-
specific monoclonal IgE and DNP-bovine serum albumin (BSA) were from
Sigma (St. Louis, Mo.), and phosphatidylethanol (PEtOH) standard for the PLD
assay was from Avanti-Polar Lipid (Alabaster, Ala.).
Extraction of RNA and reverse transcription-PCR (RT-PCR). Total RNA was
isolated from RBL-2H3 cells by using TRIzol reagent (Invitrogen) and was
reverse transcribed with the Superscript first-strand synthesis system (Invitrogen)
according to the manufacturer’s protocol. PCR was performed at 94°C for 45 s
at 55°C for 45 s and at 72°C for 60 s for 30 cycles. The following primer pairs were
used: rat PLD1 forward (5-GTGGGCAGTGTCAAGCGGGTCACC-3) and
reverse (5-GCCAAAACCTAGTCTCCCCATGGA-3), rat PLD2 forward (5-
ATGACTGTAACCCAGACGGCACTC-3) and reverse (5-CAGCTCCTGAA
AGTGTCGGAATTT-3), and rat GAPDH forward (5-GTGGAGTCTACTG
GCGTCTTC-3) and reverse (5-CCAAGGCTGTGGGCAAGGTCA-3).
Cloning of Lyn, Fyn, Fgr, Src, and Yes from RBL-2H3 cells and mutation of
HA-PLD2. The Src kinases were cloned into pCMV Vector (Stratagene, La Jolla,
Calif.) by PCR amplification with the following primers: 5-TCCCCGCGGCA
CCGCGAGCGAGAAATATG-3 and 5-CCGCTCGAGTGGCTGCTGCTGA
TACTGC-3 for LynB, 5-GGAATTCGAGCTTGGATAATGGGCTGTG-3
and 5-GCGTCGACTCACAGGTTTTCACCGGGCTG-3 for Fyn, 5-GGAA
TTCGGAATGGGCTGTGTGTTCTGC-3 and 5-CCGCTCGAGGTCAGGC
TATGTCTGGTCTCC-3 for Fgr, 5-GGAATTCATGGGCAGCAACAAGAG
CAAG-3 and 5-CCGCTCGAGCACACAGTTCCTATAGGTTCT-3 for c-Src,
and 5-TTCCCGCGGATGGGCTGCATTAAAAGTAAAG-3 and 5-GCGTC
GACTTATAAATTTTCTCCTGGTTGG-3 for Yes. Sequence and expression
was confirmed by sequencing and Western blot analysis. Plasmids for human
HA-PLD1b and murine HA-PLD2 (13) were kindly supplied by Michael A.
Frohman (Institute for Cell and Developmental Biology, State University of New
York, Stony Brook). Mutations of HA-PLD2 were performed by using a Quik-
Change site-directed mutagenesis kit (Stratagene) with the following primers:
PLD2 Y11F, 5-GAAGAACCTCTTTCCCTTTGGGGACTATCTGAAC-3;
PLD2 Y14F, 5-CTGGCTGGAGTTCAGAAAGTCCCCATAGGGAAAG-
3; PLD2 Y165F, 5-GCCAGCAAACAGAAATTCTTGGAAAATTACCTC-
3; and PLD2 Y470F, 5-CAGGTCAGTCAGTCGGAATTGCACGTCATCCC
AG-3.
Transient transfection of cells with HA-PLDs, PLD2(K758R) mutant, and Src
kinases. RBL-2H3 cells were grown as monolayers in minimal essential medium
with Earle’s salts, supplemented with glutamine, antibiotics, and 15% fetal bo-
vine serum (3). Cells were transiently transfected with each DNA preparation
(25 g/2  107 cells unless stated otherwise) by electroporation (Bio-Rad Gene-
Pulser; 960 F, 250 V). Successful transfection was confirmed by Western blot-
ting and by assay of PLD activity. Cells were used within 48 h of transfection.
Synthesis and transfection of siRNA against Fyn and Fgr. Short hairpin
siRNA constructs were designed around 21 nucleotide sequences that matched
rat fyn (open reading frame nucleotides 984 to 1004) and fgr (open reading frame
nucleotides 871 to 891). Sense and antisense RNA oligonucleotides that con-
tained the loop sequence, CCACC, were synthesized by Lofstrand (Rockville,
Md.) and cloned into the psiRNA-hH1zeo vector (Invivogen, San Diego, Calif.).
The siRNA constructs (25 g of DNA) were transfected into 2  107 cells, and
cells were incubated in 500 g of zeocin/ml for selection. Two weeks later cells
were harvested for the studies described.
Cell stimulation, immunoprecipitation of HA-PLDs, and immunoblotting.
Transfected cells (1.0  106 cells/10-cm petri dishes) were washed with fresh
growth medium 4 h after transfection and incubated with 50 ng of IgE/ml for 3 h.
The cells were washed, and medium was replaced with a PIPES [piperazine-
N,N-bis(2-ethanesulfonic acid)]-buffered medium (25 mM PIPES [pH 7.2], 159
mM NaCl, 5 mM KCl, 0.4 mM MgCl2, 1 mM CaCl2, 5.6 mM glucose, and 0.1%
fatty acid-free fraction V from bovine serum). Cells were stimulated with 25 ng
of DNP-BSA/ml for 3 min or as indicated, chilled with ice to terminate stimu-
lation, and then washed twice with ice-cold phosphate-buffered saline (PBS).
Cells were lysed in 0.5 ml with ice-cold lysis buffer (20 mM HEPES [pH 7.5], 150
mM NaCl, 1% Nonidet P-40, 10% glycerol, 60 mM octyl--glucoside, 10 mM
NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 2.5 mM nitrophe-
nylphosphate, 0.7 g of pepstatin/ml, and a protease inhibitor cocktail tablet).
Lysates were kept on ice for 30 min and then centrifuged 15,000  g for 15 min
at 4°C. The supernatant fraction was “precleared” by addition of 50 l of protein
G-agarose. After gentle rocking for 1 h, the mixture was centrifuged. Samples of
the supernatant fraction of equal protein content were used for immunoprecipi-
tation. HA-PLDs were immunoprecipitated by overnight incubation (at 4°C with
gentle rocking) with agarose-conjugated anti-HA antibody. The agarose was
washed five times with a washing buffer (20 mM HEPES [pH 7.5], 150 mM NaCl,
0.1% Nonidet P-40, 10% glycerol, 10 mM NaF, 1 mM Na3VO4, 1 mM phenyl-
methylsulfonyl fluoride, 2.5 mM nitrophenylphosphate, 0.7 g of pepstatin/ml,
and a protease inhibitor cocktail tablet) and dissolved in 2 Laemmli buffer (29).
Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to nitrocellulose membranes (BA85;
Schleicher & Schuell). The immunoreactive proteins were detected by use of
horseradish peroxidase-coupled secondary antibodies and enhanced chemilumi-
nescence according to the manufacturer’s instructions (Amersham Pharmacia
Biotech).
Assay of immunoprecipitated HA-PLD mutants in vitro. Immunoprecipitated
wild-type and mutated PLDs were assayed by measurement of the release of
[3H]choline from the PLD substrate, (choline-[3H]methyl)dipalmitoylphosphati-
dylcholine. For this assay, 80 l of each immunoprecipitated sample was added
to 25 l of a vesicle preparation that consisted of a mixture of phospholipids and
140,000 dpm of labeled substrate diluted with buffer to make a final volume of
125 l exactly as described by Massenburg et al. (34). The mixture was incubated
at 37°C for 1 h. The reaction was terminated by the addition of 1 ml of a mixture
of chloroform-methanol-concentrated HCl (50:50:0.3 [vol/vol/vol]), followed by
the addition of 0.35 ml of 1 M HCl–5 mM EGTA. The aqueous phase was
assayed for [3H]choline by liquid scintillation counting.
Measurement of PLD activity in intact cells by the transphosphatidylation
assay. PLD-transfected RBL-2H3 cells were incubated for 3 h with 50 ng of
IgE/ml in complete growth medium in 12-well plates (3.5  105 cells/well).
[3H]myristic acid at 2 Ci/ml was added for the final 90 min of incubation. Cells
were then incubated in PIPES-buffered medium (9) in the presence of 1%
ethanol for 10 min before stimulation with 25 ng of DNP-BSA/ml for 3 min.
[3H]PEtOH was assayed by minor modifications of a previously described pro-
cedure (2). The reaction was terminated by the addition of 1.5 ml of chloroform–
methanol–4 N HCl (100:200:2 [vol/vol/vol]) to form a single phase. The mixture
was separated into two phases by addition of 0.5 ml of chloroform that contained
unlabeled phosphatidic acid and PEtOH (60 g of each), as well as 0.5 ml of 0.1
N HCl. The phospholipids in the lower chloroform phase were separated by
thin-layer chromatography. The [3H]PEtOH “spot” was excised and assayed by
liquid scintillation counting (2).
Phosphorylation of HA-PLD2 by Src kinases in vitro. The reversible immu-
noprecipitation system, Catch and Release (Upstate), was utilized according to
the manufacturer’s protocol to measure phosphorylation of HA-PLD2 in vitro.
In this procedure, the cell lysate was diluted to 1 mg of protein/ml with the
lysis-wash buffer, and 500 l of the diluted lysates was transferred to spin
columns. Then, 4 g of antibody to HA-PLD2 or the Src kinases and 10 l of the
antibody capture affinity ligand were added to the diluted lysate. The spin
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columns were then gently rocked for 15 min at room temperature before cen-
trifugation at 4,200 rpm for 10 min. The columns were washed twice with the
lysis-wash buffer. HA-PLD2 and the Src kinases were eluted from the columns
and analyzed by Western blotting. The phosphorylation of HA-PLD2 by Src
kinases was assessed as follows. The eluates were added to a solution of 20 mM
Tris (pH 7.4), 10 mM MgCl2, 1 mM dithiothreitol, 10 g/ml of 4-(2-aminoeth-
yl)benzensulfonyl fluoride, 0.1 mM EDTA, 0.1 mM sodium orthovanadate, 1 g
of aprotinin/ml, 0.1 g of pepstatin A/ml, 0.05 g of leupeptin/ml, 8 mM -glyc-
erophosphate, 2.5 mM NaF, 50 M ATP, and 10 Ci of [32P]ATP. The mixture
was incubated for 30 min at 30°C. Proteins were separated by SDS-PAGE and
tyrosine phosphorylated, and 32P-labeled HA-PLD2 were detected by immuno-
blotting with antiphosphotyrosine antibody and by autoradiography, respectively.
Measurement of Src kinase activity. Src kinases (Lyn, Fyn, Fgr, and Src) were
immunoprecipitated from cell lysates with the kinase-specific antibodies noted
above. The immunoprecipitates were assayed for kinase activity by use of an in
vitro kinase assay kit (Tyrosine Kinase Assay Kit for Chemiluminescence De-
tection; Upstate) according to the manufacturer’s instructions.
Measurement of degranulation. Secretion of granules was determined by
measuring the release of the granule marker, -hexosaminidase with a colori-
metric assay in which the release of p-nitrophenol from p-nitrophenyl-N-acetyl-
-D-glucosaminide is measured (41). Values were expressed as the percentage of
intracellular -hexosaminidase that was released into the medium.
Confocal microscopy. RBL-2H3 cells were transfected with wild-type or mu-
tated HA-PLDs by electroporation as described above. The cells were then
suspended in complete growth medium, transferred to Lab-Tek chambered cov-
erslips (Nalge Nunc International, Naperville, Ill.) and then incubated overnight
at 37°C. The cultures were washed three times with phosphate-buffered saline
(PBS). Cultures were fixed in 4% formaldehyde in PBS for 10 min, washed, and
permeabilized with 0.5% Triton X-100 for 15 min. The fixed cells were washed
again before incubation for 60 min with a blocking reagent, 1% bovine serum
albumin in PBS. The coverslips were incubated for 2 h with a solution of the
primary antibody in 1% bovine serum albumin in PBS, washed, and then incu-
bated with rhodamine-conjugated secondary antibody for 45 min. The coverslips
were washed, and mounts were prepared by using a Prolonged Antifade Kit
(Molecular Probes, Eugene, Oreg.). Confocal images were obtained with a Bio-
Rad MRC 1024 confocal laser-scanning microscope with an Apochromat 60
objective lens.
RESULTS
Tyrosine phosphorylation of PLD2 and its suppression by
the Src kinase inhibitor, PP2. Analysis by RT-PCR revealed
that RBL-2H3 cells express message for PLD2 and less-abun-
dant message for PLD1b (Fig. 1A). In the absence of reliable
immunoprecipitating antibodies for these PLDs, studies were
conducted with RBL-2H3 cells made to express human HA-
PLD1b (hereafter referred to as HA-PLD1) or murine HA-
PLD2. Immunoprecipitation of the HA-tagged PLDs and im-
munoblotting with antibodies against HA and phosphotyrosine
showed that HA-PLD2 but not HA-PLD1 was tyrosine phos-
phorylated (Fig. 1B). The extent of PLD2 phosphorylation
(Fig. 1B) and the PLD activity (Fig. 1C) were increased after
antigen stimulation. The increased phosphorylation was evi-
dent within 1.5 min and reached a maximum by 15 min (Fig.
1D). The concentration of antigen used (25 ng/ml) for this and
FIG. 1. RBL-2H3 cells express message for PLD1b and PLD2, but only PLD2 is tyrosine phosphorylated after antigen stimulation. (A) The
presence of mRNA for the PLD isoforms in RBL-2H3 cells was determined by RT-PCR. RBL-2H3 cells were then transiently transfected with
HA-PLD1b or HA-PLD2 DNA-constructs and primed with DNP-specific IgE before stimulation with antigen (25 ng of DNP-BSA/ml) for 3 min
(B and C) or the times indicated (D). The PLDs were immunoprecipitated with anti-HA antibody and separated by SDS-PAGE for detection of
the HA-PLDs and tyrosine phosphorylated PLDs (pY-PLD) with anti-HA and antiphosphotyrosine antibodies. Representative immunoblots from
three experiments, as well as the average values for relative densities of the phosphorylated PLDs, as determined by densitometry, are shown in
panels B and D. Transfected cells were also labeled with [3H]myristic acid for measurement of PLD activity by the transphosphatidylation assay
in intact cells to verify that transfection with HA-PLD2 also enhanced cellular PLD activity (shown in panel C). The results are expressed as the
percentage of 3H-lipid fraction recovered as [3H]PEtOH as described in Materials and Methods. Values are means 	 the standard error of the
mean (SEM) of three experiments. Key: NS, nonstimulated; Ag, antigen stimulated; pY-PLD, tyrosine phosphorylated PLD1 and PLD2;
, significant difference at the P 
 0.01 level.
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subsequent experiments elicited maximal degranulation of
RBL-2H3 cells (40 to 50% [data not shown]).
Various kinase inhibitors were tested to identify the type of
kinase involved in PLD2 phosphorylation. Of these, the Src
kinase inhibitor PP2 alone suppressed antigen-induced tyro-
sine phosphorylation of PLD2 (Fig. 2A). Piceatannol, wort-
mannin, and Ro31-7549 (which inhibit Syk, phosphatidylinosi-
tol 3-kinase, and PKC, respectively) were inactive to indicate
that only Src kinases regulated, either directly or indirectly,
tyrosine phosphorylation of PLD2. The inhibition of PLD2
phosphorylation by PP2 was concentration dependent and was
apparent with as little as 2 M PP2 (Fig. 2B). Near-maximal
inhibition was observed with 6.0 M PP2, and the estimated
concentration for 50% inhibition was 3.0 M.
Coexpression of Fyn or Fgr enhances tyrosine phosphory-
lation of expressed HA-PLD2. Endogenous Lyn, Fyn, Fgr, and
c-Src were detected in RBL-2H3 cells by immunoblotting (Fig.
3A) and by cloning their cDNA (see Materials and Methods).
The cloned Src kinases were coexpressed with HA-PLD2 to
identify which of them could phosphorylate PLD2 in vivo (Fig.
3B). Both basal and antigen-stimulated tyrosine phosphoryla-
tion of HA-PLD2 were enhanced in cells cotransfected with
Fyn or Fgr compared to cells transfected with the vector alone.
Cotransfection with Lyn produced minimal enhancement of
phosphorylation and cotransfection with c-Src, if anything, ap-
peared to suppress antigen-induced HA-PLD2 phosphoryla-
FIG. 2. Tyrosine phosphorylation of PLD2 is suppressed by the Src
kinase inhibitor, PP2. RBL-2H3 cells were transiently transfected with
HA-PLD2 cDNA and primed with DNP-specific IgE. PP2 (20 M),
piceatannol (120 M; Pi), wortmannin (100 nM; Wort), or Ro31-7549
(10 M; Ro31) (A) or the indicated concentrations of PP2 (B) were
added 10 min before stimulation with 25 ng of DNP-BSA/ml (Ag) for
3 min. Some cells were left unstimulated (NS). HA-PLD2 was immu-
noprecipitated with anti-HA antibody and separated by SDS-PAGE
for detection of HA-PLD2 with anti-HA antibody and tyrosine phos-
phorylated PLD2 (pY-PLD2) with antiphosphotyrosine antibody.
Representative immunoblots from three experiments, and average val-
ues for relative densities of the phosphorylated PLD2, as determined
by densitometry, are shown.
FIG. 3. Tyrosine phosphorylation of PLD2 is enhanced upon overexpression of Fyn or Fgr. Immunoblots of lysates of RBL-2H3 cells were
prepared for detection of endogenous Src kinases (A). RBL-2H3 cells were cotransfected with cDNA constructs for HA-PLD2 and the indicated
Src kinases or vector. Cells were then primed with DNP-specific IgE. Cells were not stimulated (NS) or stimulated with 25 ng of DNP-BSA/ml (Ag)
for 3 min. HA-PLD was immunoprecipitated (IP) with anti-HA antibody, and immunoblots were probed with antiphosphotyrosine and anti-HA
antibodies for detection of tyrosine phosphorylated PLD2 (pY-PLD2) and HA-PLD2 (PLD2). Average values for relative densities of phosphor-
ylated PLD2, as determined by densitometry, are indicated also (B, upper panel). Immunoblots were also prepared from cell lysates to verify
expression of the individual Src kinases; representative immunoblots from three experiments are shown in panel B. (C) The individual Src kinases
were also immunoprecipitated from the cell lysates for assay of Src-kinase activity by the chemiluminescence procedure described in Materials and
Methods. Values are means 	 the SEM from three experiments, and chemiluminescence is expressed as counts per second (cps).
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tion. The differences in phosphorylation were not attributable
to differences in activities of the Src kinases in transfected cells
(Fig. 3C). For example, immunoprecipitation and assay of Fgr
indicated that this kinase exhibited the least activity while
promoting the most abundant phosphorylation of PLD2 (com-
pare Fig. 3C and B). Conversely, c-Src kinase exhibited the
highest activity while promoting the least phosphorylation of
PLD2. Also, Lyn and Fyn transfected cells possessed similar
kinase activities but differed in their ability to phosphorylate
PLD2 as noted above. However, we detected no increase in
activity of any of these kinases upon antigen stimulation (see
Fig. 3C). Others have noted such lack of activation of Fyn and
Lyn in antigen-stimulated RBL-2H3 cells (Juan Rivera, Na-
tional Institute of Arthritis and Musculoskeletal and Skin Dis-
eases, National Institutes of Health [unpublished data]), pos-
sibly because the proportion of available intracellular Src
kinase that is recruited by FcεRI during stimulation is rela-
tively small (17, 61).
The enhancement of HA-PLD2 phosphorylation by Fyn and
Fgr was dependent on the level of expression of either Src
kinase and showed a progressive increase with increasing levels
of the expressed Src kinase (upper panels of Fig. 4). No such
increase was observed in cells cotransfected with increasing
amounts of Lyn cDNA (data not shown) to suggest that PLD2
was not a substrate for Lyn kinase activity. The time course of
antigen-induced HA-PLD2 phosphorylation in cells cotrans-
fected with either Fyn or Fgr (lower panels, Fig. 4A and B) was
comparable to that observed in cells not transfected with these
kinases (i.e., Fig. 1D). That is, increased phosphorylation was
apparent at 1 min and reached a maximum by 15 min. Of
particular interest, both Fyn and Fgr coimmunoprecipitated
with HA-PLD2 in nonstimulated cells, but the extent of this
association appeared to decrease after stimulation with antigen
(lower panels, Fig. 4A and B). This result strongly suggests that
phosphorylation and/or activation of PLD2 promotes dissoci-
ation of the Src kinases from PLD2 early in the FcεRI-medi-
ated cascade of signaling events. The reason for this dissocia-
tion is unknown and requires further investigation.
Other experiments showed that coexpression of Fyn and Fgr
enhanced phosphorylation of HA-PLD2 to a greater extent
than expression of the individual kinases in both nonstimulated
cells and antigen-stimulated cells. A typical immunoblot is
shown in Fig. 5A. Densitometric analysis of the immunoblots
suggested that the enhanced phosphorylation was either addi-
tive or possibly synergistic (Fig. 5B).
Fyn and Fgr, but not Lyn, phosphorylate HA-PLD2 in vitro.
Studies were conducted in vitro to determine whether or not
immunoprecipitated Fyn and Fgr phosphorylate PLD2 di-
rectly. HA-PLD2, Lyn, Fyn, and Fgr were recovered by immu-
noprecipitation from cells made to overexpress these proteins.
The immunoprecipitated Src kinases were then incubated with
immunoprecipitated HA-PLD2 in the presence of [32P]ATP as
FIG. 4. Tyrosine phosphorylation of PLD2 is dependent on level of expression of Fyn and Fgr and on duration of stimulation with antigen.
RBL-2H3 cells were cotransfected with cDNA constructs for HA-PLD2, along with vector, Fyn, or Fgr. For the upper panels, the amount of cDNA
was varied as indicated and for the lower panels, 6.25 g of DNA was used. Cells were primed with DNP-specific IgE and cells were either not
stimulated (NS) or stimulated with 25 ng of antigen DNP-BSA/ml (Ag) for 3 min or for the times indicated in the lower panels. HA-PLD2 was
immunoprecipitated (IP) for detection of tyrosine phosphorylated PLD2 (pY-PLD2) and HA-PLD2 (all panels) and for coimmunoprecipitated
Fyn or Fgr (lower panels). In addition, immunoblots prepared from cell lysates were probed for Fyn or Fgr as indicated. Representative
immunoblots from three experiments are shown.
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described in Materials and Methods. Both Fyn and Fgr caused
phosphorylation of PLD2, as indicated by formation of 32P-
labeled PLD2 and an increase in levels of tyrosine phosphor-
ylated PLD2, whereas Lyn was inactive in this regard (Fig. 6A).
Measurement of Src kinase activity revealed that the immuno-
precipitates of Lyn and Fyn contained comparable levels of
activity, whereas immunoprecipitates of Fgr contained 30%
less activity (Fig. 6B). Therefore, the failure of Lyn to phos-
phorylate HA-PLD2 was not the result of inherently low Lyn
kinase activity in the immunoprecipitates.
Evidence that Fyn and Fgr regulate phosphorylation and
activation of PLD2, as well as degranulation. To assess the
physiological relevance of tyrosine phosphorylation of PLD2
by Fyn and Fgr, cells were transfected with kinase-specific
siRNAs to suppress the expression of these kinases. Transfec-
tion with siRNA targeted against Fyn or Fgr resulted in sup-
pression of expression of the targeted kinase, tyrosine phos-
phorylation of PLD2 (Fig. 7A), and degranulation (Fig. 7B).
Both siRNAs were equally effective in suppressing degranula-
tion.
Other experiments were designed to determine whether
PLD2 itself was regulating degranulation. Two approaches
were used. The first took advantage of the PLD-catalyzed
transphosphatidylation reaction in which cells were incubated
FIG. 5. Fyn and Fgr together enhance phosphorylation of PLD2 in vivo. RBL-2H3 cells were cotransfected with cDNA constructs for HA-
PLD2 along with vector, Fyn, Fgr, or the combination of the two Src kinases. Cells were stimulated with antigen (Ag) or not stimulated (NS) for
3 min, and immunoprecipitates (IP) of HA-PLD2 and cell lysates were prepared for the detection of tyrosine-phosphorylated PLD2 (pY-PLD2),
HA-PLD2, Fyn and Fgr as described for previous figures. Representative blots (A) and densitometric data (B) from two experiments are shown.
FIG. 6. Fyn and Fgr phosphorylate PLD2 in vitro. Separate batches of cells were made to overexpress HA-PLD2, Lyn, Fyn, or Fgr, and each
of these proteins was immunoprecipitated. (A) The indicated mixtures of these proteins were incubated with [32P]ATP, and the proteins were
separated by SDS-PAGE for the detection of tyrosine phosphorylated PLD2 (pY-PLD2) with antiphosphotyrosine antibody, [32P]PLD2 by
autoradiography, and the indicated Src kinases as described in Materials and Methods. The results shown are representative of three experiments.
(B) In addition, the immunoprecipitated Src kinases were assayed for kinase activity. Values are means 	 the SEM from three experiments and
are expressed as a percentage of the activity of immunoprecipitated Lyn. BL, assay blank.
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with 50 mM 1-butanol which diverts production of the PLD
product, phosphatidic acid, to phosphatidylbutanol (62). This
strategy was used to unmask the physiological role of phospha-
tidic acid because there are no cell permeable inhibitors of
PLD. As shown in Fig. 8A, antigen-stimulated degranulation
was suppressed by 1-butanol but not by tertiary-butanol, which
is not a substrate for transphosphatidylation and serves as a
control for nonspecific effects of the alcohol. The second ap-
proach utilized a catalytically inactive mutant of HA-PLD2
(K758R) (55). Expression of this mutant blocked the antigen-
induced activation of PLD (Fig. 8B and inset) and degranula-
tion (Fig. 8C). Expression of wild-type HA-PLD2, as in Fig. 1,
enhanced the activation of PLD and degranulation (Fig. 8B
and C).
For further verification of the pathway Fyn/Fgr3 PLD23
degranulation, cells were made to overexpress HA-PLD2, Fyn,
and Fgr in various combinations. Coexpression of Fyn and Fgr
with HA-PLD2 enhanced the activation of PLD by antigen
compared to cells that expressed HA-PLD2 alone (Fig. 9A). In
FIG. 7. Suppression of expression Fyn and Fgr reduces tyrosine phosphorylation of PLD2 and degranulation. RBL-2H3 cells were made to
express siRNAs (RNAi) directed against Fyn or Fgr or as a control green fluorescent protein (GFP). (A) Expression of Fyn and Fgr, as well as
tyrosine-phosphorylated PLD2 (pY-PLD2) and PLD2 protein, was determined by immunoblotting. (B) Cells were also stimulated with antigen for
15 min to assess the effects on degranulation as determined by the release of the granule marker, -hexosaminidase. Values are expressed as
percentages of cellular -hexosaminidase that was released into the medium and are the means 	 the SEM of values from three experiments. The
asterisks indicate a significant decrease in release (P 
 0.01).
FIG. 8. Impairment of PLD function is associated with reduction of degranulation. (A) PLD function was altered by stimulating cells with
antigen in the absence or presence of 50 mM 1-butanol (Bu) or, as a control, tertiary butanol (tBu). (B and C) Alternatively, cells were transfected
with the catalytically inactive mutant PLD2 (K758R) or, for comparison, with the empty vector (V) or wild-type PLD2 (W). The levels of expression
of the HA-PLDs are shown in the inset in panel B. As noted in the text, 1-butanol but not tertiary butanol subverts the production of phosphatidic acid
to phosphatidylbutanol. Cells were stimulated with antigen for 15 min for measurement of the release of the granule marker, -hexosaminidase
(A and C), and for PLD activity in [3H]myristate-labeled cells (B) as described in previous legends. Degranulation is expressed as a percentage of
cellular -hexosaminidase that is released into the medium (A) or as a percentage of release observed in vector-expressing cells (C). PLD activity is
expressed as a percentage of 3H-lipid fraction recovered as [3H]PEtOH. Values are means 	 the SEM from three experiments, and asterisks indicate
a significant difference from antigen-stimulated cells in absence of butanol (A) or cells expressing wild-type PLD2 (, P 
 0.05; , P 
 0.01).
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addition, Fyn and Fgr individually and in combination aug-
mented degranulation in antigen-stimulated cells (Fig. 9B).
Mutational analysis reveals several sites of tyrosine phos-
phorylation that participate in PLD2 activation. Examination
of the amino acid sequences of both PLDs indicated several
tyrosines that are unique to PLD2, four (Y11, Y14, Y165, and
Y470) in rat and mouse PLD2 and two (Y165 and Y470) in
human PLD2. We investigated the effects of mutation of mu-
rine PLD2 at each of these sites (Y to F) and of all four sites
together (Y11/14/165/470F) in cells made to express these mu-
tants (Fig. 10). Antigen-stimulated phosphorylation of PLD2
was partially impaired by all single point mutations and was
virtually abolished by mutation of all four sites (Fig. 10A).
Indeed, the completely mutated PLD2 reduced the levels of
PLD2 phosphorylation to below those observed in nonstimulated
cells. A similar pattern was observed in the stimulation of PLD
activity by antigen. The individual mutations partially impaired,
and all four mutations abolished, PLD activation (Fig. 10B).
The effect of the mutations described above on the catalytic
activity of PLD was investigated by immunoprecipitation of
expressed HA-PLD2 from nonstimulated cells, followed by
measurement of PLD activity in the presence of the PLD
activator, PIP2. Mutations at Y11, Y14, and Y165 had no effect
on this activation and, therefore, did not influence the intrinsic
catalytic activity of HA-PLD2 (Fig. 10C). However, mutation
of Y470 resulted in partial impairment (50%) in activation to
indicate some possible loss of catalytic activity. The effects of
the mutations on the cellular location of HA-PLD2 was also
investigated by confocal microscopy (Fig. 10D). As in previous
studies (9), expressed HA-PLD2 was located primarily in the
plasma membrane. Mutation of Y14 clearly caused aberrant
localization of HA-PLD2, whereas the other individual muta-
tions did not do so. Although the role of Y14 and Y470 phos-
phorylation is uncertain because of the caveats noted above,
the studies do indicate that the mutations Y11F and Y165F
impeded phosphorylation and activation of PLD2 without im-
pairment of catalytic activity and localization of PLD2.
Further examination of the role of Src-mediated phosphor-
ylation on PLD activation and degranulation. To examine
further the possible consequences of enhanced tyrosine phos-
phorylation of PLD2, cells were stimulated in the absence or
presence of the phosphatase inhibitor, sodium orthovanadate.
Sodium orthovanadate substantially enhanced antigen-stimu-
lated tyrosine phosphorylation of expressed HA-PLD2 (Fig.
11A). This effect was associated with enhanced activation of
PLD in intact cells (Fig. 11B). Therefore, phosphorylation of
PLD2 appeared to be linked to the activation of PLD. Mea-
surement of the kinetics of tyrosine phosphorylation of ex-
pressed HA-PLD2 and degranulation showed that after
antigen stimulation PLD2 phosphorylation preceded degran-
ulation and reached a maximum by 15 min or at a time when
the rate of degranulation was declining (Fig. 12A and B).
Suppression of endogenous PLD activity by the Src kinase
inhibitor, PP2, was closely correlated with suppression of de-
granulation (Fig. 12C and D). The estimated 50% inhibitory
concentration for PP2 was 3.0 M or a value identical to that
observed for the suppression of phosphorylation of expressed
HA-PLD2 (Fig. 2). These data were thus entirely consistent
with the notion that PLD regulated degranulation and that Src
kinase-mediated phosphorylation of PLD2 might be essential
for this regulation.
FIG. 9. Coexpression of Fyn or Fgr with HA-PLD2 enhances PLD activation and degranulation. RBL-2H3 cells were cotransfected with cDNA
constructs for HA-PLD2, along with Fyn, Fgr, or both Src kinases. The activation of PLD in [3H]myristate-labeled cells (A) and degranulation
(B) after stimulation of cells with antigen for 3 min were determined as described for previous figures. The data are expressed as the percentages
of 3H-phospholipids recovered as [3H]PEtOH (A) or the enhancement of degranulation relative to that observed in cells made to express
HA-PLD2 alone (B). The stimulated release of -hexosaminidase in the latter cells was 17%. Values are the mean value from three experiments.
Bars indicate 	 the SEM, and the asterisk indicates a significant increase in response at P 
 0.05.
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DISCUSSION
Antigen-induced release of preformed inflammatory medi-
ators from mast cell granules is the primary cause of immediate
symptoms of IgE-mediated allergic diseases. Recent studies
suggest that activation of PLD is an absolute requirement for
the stimulated release of granules (7, 10, 58). As reported here,
PLD2, which is probably the major PLD isoform in RBL-2H3
cells, is phosphorylated in vitro and in vivo through the actions
of the Src kinases Fyn and Fgr. Furthermore, this phosphory-
lation is associated with activation of PLD and degranulation
in antigen-stimulated mast cells. These findings point to a
mechanism for the activation of PLD2 by the IgE receptor,
FcεRI, and provide additional evidence for an essential role
for PLD in mast cell degranulation. However, an additional
signal or signals such as the production of PIP2 by type I
phosphatidylinositol 4-phosphate 5-kinase (23) are probably
required for full activation of PLD2 in vivo for reasons to be
discussed later.
The activation of signaling pathways in antigen-stimulated
mast cells is dependent initially on the interaction of FcεRI
with the Src kinases Lyn and Fyn and subsequently on the
downstream activation of Syk and other tyrosine kinases (45).
However, propagation of the full array of activating signals is
thought to require the assembly of two distinct clusters of
signaling molecules at the plasma membrane (46). One is as-
sembled around the linker for activation of T cells (LAT), and
the other is assembled around the Grb2-associated binder-2
(Gab2). The LAT cluster of proteins enables propagation of
Syk-mediated signals. These signals include the phosphatidyl-
inositol 3-kinase-dependent phosphorylation of Tec kinases,
Btk and Itk, which in turn phosphorylate and activate PLC1
and PLC2 to promote a calcium signal through the genera-
tion of inositol 1,4,5-trisphosphate (47). The Gab2 cluster con-
sists of Fyn and the Src homology 2 domain-containing protein
tyrosine phosphatase, SHP-2, in addition to phosphatidylino-
sitol 3-kinase. Less is known about the function of this cluster,
but it appears to facilitate phosphatidylinositol 3-kinase-de-
pendent phosphorylation of the survival factor Akt by the
phosphoinositide-dependent kinase and the activation of PKC
(20, 45). These clusters appear to localize in distinct but dif-
ferent regions of the plasma membrane (60).
Current models for mast cell activation, such as the one
described above, do not accommodate PLD because its link-
ages to FcεRI are unknown. Nevertheless, our results suggest
FIG. 10. Mutation of tyrosine sites that are unique to PLD2 impair phosphorylation and activation of PLD2. Cells were made to express
HA-PLD2 with point mutations (Y to F) at tyrosine residues 11, 14, 165, or 470 or all four residues (all), as well as HA-PLD2 (Wild or W).
(A) Cells were stimulated for 3 min with antigen (Ag) or left unstimulated (NS) for immunoprecipitation and immunoblotting for detection of
tyrosine-phosphorylated HA-PLD2 (upper bands) and HA-PLD (lower bands). The blots are representative of three such experiments. (B) The
PLD activity was also determined after cells were labeled with [3H]myristic acid for the determination of cellular PLD activity by the transphos-
phatidylation assay. The data are expressed as the fold increase in activity in antigen-stimulated cells versus the basal activity in nonstimulated cells.
(C) Immunoprecipitates of wild-type and mutated HA-tagged PLDs from lysates of nonstimulated cells were assayed for intrinsic PLD activity in
vitro in the presence of PIP2. The data are expressed as the percentage of activity observed with immunoprecipitated wild-type PLD2. Values in
panels B and C are the means 	 the SEM of three experiments, and asterisks indicate significant difference from values obtained with wild-type
PLD2 (, P 
 0.05; , P 
 0.01). (D) In addition, cells were made to express the HA-PLD2 mutants and were examined by confocal microscopy
to determine the intracellular distribution of the mutated PLDs.
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that PLD2 is linked to FcεRI through Fyn and possibly Fgr. In
studies to be reported elsewhere, PLD2 becomes localized
within discrete micropatches on the plasma membrane after
antigen stimulation. Also, tyrosine phosphorylation of PLD2 is
prevented by prior treatment of RBL-2H3 cells with methyl-
-cylodextrin, a lipid raft dispersing agent. It is likely, there-
fore, that the interaction of PLD2 with Fyn occurs within
specialized domains of the plasma membrane. The aforemen-
tioned association of Fyn with Gab2 suggest that PLD2 possi-
bly associates with the Gab2/Fyn complex. If this scenario is
correct, the interaction of PLD2 with the Gab2/Fyn complex
might provide one signal for degranulation and complement
other essential signals that are mediated via LAT, namely, the
activation of PLC for the generation of a calcium signal.
With respect to Fgr, this Src kinase has not been previously
implicated in FcεRI-mediated signaling in mast cells. Fgr is
most highly expressed by mature blood granulocytes and
monocytes, as well as tissue macrophages. Although Fgr neg-
atively regulates Fc receptor-mediated phagocytosis in mac-
rophages (19), it appears to play a positive role in integrin- or
chemokine-mediated responses in macrophages (52), eosino-
phils (14, 57), and neutrophils (38). Of particular interest, Fgr
has been identified as a downstream target of PLD-derived
phosphatidic acid in neutrophils stimulated with chemotactic
peptide (50). In this situation, Fgr tyrosine phosphorylating
activity was found to be dependent on phosphatidic acid (50).
If this finding is applicable to antigen-stimulated mast cells, the
possibility exists that PLD2 might promote its own phosphor-
ylation by Fgr through the production of phosphatidic acid. A
possible analogous situation is the ability of phosphatidic acid
to activate phosphatidylinositol 4-phosphate 5-kinase (23)
which, as noted earlier, catalyzes the production of PIP2, the
only known stimulant of PLD2 activity. Both Fgr and phos-
phatidylinositol 4-phosphate 5-kinase may thus provide the
means of sustaining or amplifying PLD2 activation.
There are indications from previous work that Src kinases
interact with PLD2. Src kinase(s) is thought to be responsible
for enhanced PLD activity in v-Ras-transformed cells (24),
whereas other studies indicate that c-Src phosphorylates PLD2
and to a much lesser extent PLD1 in EGF-stimulated cells
through direct interaction of the N-terminal phox (PX) domain
of PLD2 with the catalytic domain of c-Src (1). This interaction
did not alter PLD activity but rather enhanced Src catalytic
activity possibly as a consequence of the production of phos-
phatidic acid by PLD.
It would appear from our studies in mast cells that tyrosine
phosphorylation of PLD2 leads to activation of PLD2, but it is
not clear whether this phosphorylation directly activates PLD2
or promotes association of PLD2 with other regulatory mole-
cules or signaling complexes. Increased tyrosine phosphoryla-
tion of PLD2 is associated with increased PLD2 activity (Fig. 1
and 11) and mutation of the tyrosine residues that are phos-
phorylated reduces the activation of PLD2 (Fig. 10B). How-
ever, the effects of mutation of Tyr-14 and Tyr-470 are com-
plex. Mutation of Tyr-14 leads to aberrant intracellular
distribution of PLD2, dissociation from Fyn and Fgr, and de-
creased phosphorylation (Fig. 10). The reason for the mislo-
calization of the Y14 mutant is still under investigation but
current studies indicate that it colocalizes with PLD1 on se-
cretory granules (unpublished data). If so, Y14 may allow
proper localization of PLD2 on the plasma membrane at least
in rodent mast cells. The effect of mutation at Tyr-470 is
ambiguous because of the impaired activation of the Tyr-470
mutant by PIP2 (Fig. 10C). Nevertheless, this does not exclude
the possibility that basal phosphorylation of Tyr-470 is critical
for basal PLD2 activity. Of the four tyrosines that are phos-
phorylated, only Tyr-165 and Tyr-470 are conserved in rat,
mouse, and human PLD2. It is notable that these two residues
reside in strategic locations of PLD2. Tyr-470 is close to one of
two HKD motifs, whereas Tyr-165 lies within the PX domain
of PLD2. The two PLD HKD motifs (16, 18) provide the
essential core for PLD catalytic activity (55). The precise role
FIG. 11. Sodium orthovanadate enhances antigen-induced tyrosine phosphorylation and activation of PLD2. Cells made to express HA-PLD2
were stimulated with antigen (Ag) or not stimulated (NS) for 3 min in the absence or presence of 100 M sodium orthovanadate. (A) HA-PLD2
was immunoprecipitated from whole-cell lysates, and immunoblots were prepared for detection of tyrosine phosphorylated PLD2 (pY-PLD2) and
HA-PLD2 (PLD2). (B) Cells were also labeled with [3H]myristic acid for the assay of PLD activity in intact cells by the transphosphatidylation
assay. The values are means 	 the SEM from three experiments, and the asterisk indicates a significant difference (P 
 0.01).
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of the PX domain is unknown (18) but deletion of the NH2-
terminal region, which includes the PX domain and a pleck-
strin homology domain, disrupts the regulation of PLD activity
and the association of PLD1 with membranes (22, 53, 54, 56).
One proposal is that the NH2-terminal region normally re-
presses PLD1 catalytic activity, and this repression is alleviated
by stimulatory molecules such as ARF, Rho, and PKC (56). A
similar scenario is envisaged for PLD2 because truncation of
the NH2-terminal domain renders PLD2 sensitive to ARF
(54). If so, phosphorylation Tyr-165 in the PLD2 PX domain
could conceivably alter the tertiary structure of PLD2 and
allow interaction of PLD2 with other regulatory molecules.
The present study also indicates a close correlation between
PLD2 tyrosine phosphorylation and degranulation. PLD2
phosphorylation preceded degranulation (Fig. 12A and B),
both events were equally sensitive to inhibition of Src kinase
activity (Fig. 7 and 12C and D), and both were enhanced by
coexpression of PLD2 and the Src kinases (Fig. 9). Other
correlations were noted between the activation of PLD and
degranulation (Fig. 8) in support of previous findings (9).
These findings, therefore, point to the possibility that PLD2
tyrosine phosphorylation is a regulatory step in degranula-
tion.
In summary, our findings indicate that PLD2, which is asso-
ciated primarily with the plasma membrane in RBL-2H3 cells,
is phosphorylated at multiple sites by FcεRI-activated Fyn and
Fgr. This is the first indication of a direct link between FcεRI
and PLD2. Furthermore, this phosphorylation is essential for
PLD activation and possibly degranulation in vivo. Although it
is possible that the phosphorylation in itself is sufficient for
PLD2 activation, our view based on the findings described
above is that the phosphorylation of tyrosines, particularly
those located within or near the PX domain and HKD motif,
induces conformational changes of PLD2 which allow interac-
tion with other regulatory molecules. The production of phos-
phatidic acid by PLD2 could conceivably promote these inter-
actions in a manner analogous to that conceived for the
interaction of c-Src with PLD2 in response to EGF (1) as noted
above. In addition to these considerations, the rapidity of
PLD2 phosphorylation (Fig. 12A) and of the dissociation of
the Src kinase/PLD2 complex (Fig. 4) suggest that PLD2 acti-
vation is an early rather than a late event in mast cell activa-
tion. Given the key role of mast cells in allergic diseases and of
PLD in mast cell degranulation, these findings have relevance
to the pathology and treatment of mast cell-related allergic
disease.
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